UnitedHealth Group
UNH
$431.31
-1.16%
UnitedHealth Group is a diversified healthcare company that provides health insurance and healthcare services through its UnitedHealthcare and Optum segments, serving approximately 51 million members globally. As the largest private health insurer in the U.S., it leverages massive scale in employer-sponsored, self-directed, and government-backed insurance plans, while its Optum franchises span pharmacy benefits, outpatient care, and data analytics. The current investor narrative centers on the stock's recovery from a sharp selloff in early 2026, driven by improved Medicare reimbursement rates and strong Q1 earnings, though an ongoing DOJ investigation and policy dependency create debate about the sustainability of the rally.…
UNH
UnitedHealth Group
$431.31
Related headlines
Investment Opinion: Should I buy UNH Today?
Rating: Hold. UnitedHealth is a high-quality defensive business with strong cash flows, but the stock's 47.9% rally over the past year and limited upside to the average analyst target of $437.81 (+2.7%) suggest much of the recovery is priced in. The consensus Buy rating (1.67/5) supports a positive long-term view, but near-term risk-reward is balanced.
Supporting evidence: (1) Trailing P/E of 24.95x is below the 5-year average of ~28x, but above the industry average of 22.0x. (2) Revenue growth is decelerating at 1.96% YoY, limiting multiple expansion. (3) Q1 2026 operating margin of 8.0% shows recovery from Q4 2025's 0.3%, but remains below historical levels. (4) TTM free cash flow of $19.67 billion provides strong financial flexibility. The implied upside to the average target is modest, and the stock is fairly valued relative to its history and peers.
Risks & Conditions: The DOJ investigation is the biggest risk; a negative outcome could downgrade the stock to Sell. Conversely, if the investigation is resolved favorably and revenue growth reaccelerates above 5%, an upgrade to Buy would be warranted. The stock appears fairly valued given the current risk profile, with limited upside potential in the near term.
Sign up to view all
UNH 12-Month Price Forecast
UnitedHealth's outlook is balanced: the operational recovery is real, but the stock's 47.9% rally and unresolved DOJ investigation limit upside. The base case of steady earnings and modest price appreciation is most likely, with a 50% probability. A bullish resolution of the investigation could drive the stock to $492, while a negative outcome could send it back to $287 or lower. The neutral stance reflects the lack of a clear catalyst to break the current range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $475.23 and implied upside of +10.2% versus the current price.
Average Target
$475.23
0 analysts
Implied Upside
+10.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$313 - $529
Analyst target range
UnitedHealth is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean score 1.67 on a 1-5 scale). The average price target is $437.81, implying a modest 2.7% upside from the current price of $426.09. The distribution leans bullish: 10 recent ratings include 7 Buy/Overweight and 3 Hold, with no Sell ratings. The average target suggests analysts see limited near-term upside, consistent with the stock's recent rally. The target range spans from $287.00 (low) to $492.00 (high). The high target assumes continued operational recovery, margin expansion, and resolution of regulatory overhangs, while the low target prices in potential negative outcomes from the DOJ investigation or adverse policy changes. The wide spread of $205 indicates high uncertainty. Recent ratings have been stable, with no downgrades in the past month, but the lack of upgrades suggests analysts are waiting for clearer catalysts. The implied upside to the average target is modest, reflecting a balanced risk-reward at current levels.
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a mixed picture: strong operational recovery and low valuation relative to history are countered by revenue deceleration, regulatory overhangs, and limited near-term upside. The bull case rests on earnings normalization and resolution of the DOJ investigation, while the bear case highlights policy dependency and margin compression. Currently, the evidence slightly favors the bull case given the Q1 2026 earnings rebound and defensive characteristics, but the DOJ investigation outcome is the single most important swing factor that could dramatically alter the thesis.
Bullish
- Strong Earnings Recovery in Q1 2026: Q1 2026 net income of $6.28 billion and EPS of $6.90 represent a sharp rebound from Q4 2025's near-zero profit ($10 million). Operating margin improved to 8.0% from 0.3% sequentially, signaling operational recovery.
- Low Valuation Relative to History: Trailing P/E of 24.95x is below the 5-year average of ~28x, and P/B of 3.19x is well below the 5-year average of 5.0x. This suggests the stock is not pricing in aggressive growth, offering a margin of safety.
- Massive Free Cash Flow Generation: TTM free cash flow of $19.67 billion provides ample capacity for dividends, buybacks, and debt reduction. The dividend yield of 2.64% is supported by a 65.7% payout ratio, leaving room for growth.
- Defensive Business Model with Low Beta: With a beta of 0.63, UNH is 37% less volatile than the market. Its essential healthcare services provide stable demand regardless of economic cycles, making it a defensive holding.
Bearish
- Ongoing DOJ Investigation Overhang: The DOJ investigation into UNH's Medicare billing practices remains unresolved. Any adverse findings could lead to fines, reputational damage, and earnings disruption, as seen in Q4 2025's near-zero profit.
- Revenue Growth Deceleration: Q1 2026 revenue grew only 1.96% YoY, down from 10.7% in Q4 2024. This deceleration reflects a mature business facing pricing headwinds and membership constraints, limiting top-line momentum.
- Thin Net Margins and Earnings Volatility: TTM net margin is just 2.7%, dragged by Q4 2025's near-zero profit. The 22.3% gap between trailing P/E (24.95x) and forward P/E (19.38x) implies the market expects earnings growth, but any miss could trigger multiple compression.
- Stock Near 52-Week High, Limited Upside: At $426.09, UNH trades at 92.3% of its 52-week range. The average analyst target of $437.81 offers only 2.7% upside, suggesting the recovery rally is largely priced in.
UNH Technical Analysis
UnitedHealth is in a strong uptrend, with the stock up 47.9% over the past year, significantly outperforming the S&P 500's 18.4% gain. The current price of $426.09 sits at 92.3% of its 52-week range ($234.60–$461.62), indicating the stock is near the top of its range and reflecting robust momentum. This positioning suggests the market is pricing in continued operational recovery, though it also raises the risk of a pullback if sentiment shifts. Short-term momentum is accelerating: the 1-month price change is +6.6% and the 3-month change is +31.3%, both outpacing the S&P 500's respective gains of 0.3% and 4.7%. The 1-month relative strength of +6.3% confirms near-term outperformance. This acceleration aligns with the longer-term uptrend, signaling strong conviction rather than a divergence. The 52-week low of $234.60 provides key support, while the 52-week high of $461.62 is the immediate resistance. A breakout above $461.62 would signal a continuation of the rally, targeting new highs, while a breakdown below $234.60 would indicate a trend reversal. With a beta of 0.63, UnitedHealth is 37% less volatile than the market, making it a relatively defensive holding within the healthcare sector.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$235-$462
Price range past year
Annual Return
+51.3%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | +6.1% | +0.4% |
| 3m | +21.6% | +5.5% |
| 6m | +21.1% | +8.4% |
| 1y | +51.3% | +18.9% |
| ytd | +28.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
Revenue growth has decelerated: Q1 2026 revenue of $111.7 billion grew only 1.96% year-over-year, compared to 2.1% in Q1 2025 and 10.7% in Q4 2024. The UnitedHealthcare segment generated $82.99 billion in revenue, while OptumHealth contributed $4.58 billion, indicating the core insurance business drives the top line. The deceleration reflects a mature business facing pricing headwinds and membership growth constraints, though the company's scale provides stability. Profitability remains solid but compressed: Q1 2026 net income was $6.28 billion, with a gross margin of 22.7% and net margin of 5.6%. However, the trailing twelve-month net margin is just 2.7%, dragged down by a weak Q4 2025 (net income of $10 million). Operating margin improved to 8.0% in Q1 2026 from 0.3% in Q4 2025, signaling a recovery from the prior quarter's disruption. The balance sheet is healthy: debt-to-equity is 0.83, and free cash flow for Q1 2026 was $8.15 billion, with TTM free cash flow of $19.67 billion. The current ratio of 0.79 indicates adequate liquidity, and ROE of 12.8% reflects efficient capital use. The company generates sufficient cash to fund operations and dividends without external financing.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Since net income is positive, the trailing P/E ratio of 24.95x is the primary valuation metric. The forward P/E of 19.38x implies the market expects earnings growth, with the gap between trailing and forward suggesting a 22.3% earnings increase over the next year. The P/S ratio of 0.67x is low relative to the industry, reflecting the company's thin net margins. Compared to the industry average P/E of 22.0x (estimated), UnitedHealth trades at a 13.4% premium, justified by its market leadership, diversified business model, and consistent cash flow generation. The P/B ratio of 3.19x is below the 5-year average of 5.0x, indicating the stock is cheaper on a book value basis. Historically, the trailing P/E is near the lower end of its 5-year range (which peaked above 30x in 2022), suggesting the market is not pricing in aggressive growth expectations. This could represent a value opportunity if the company's earnings recovery materializes, but it also reflects uncertainty around regulatory and policy risks.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UnitedHealth's earnings are volatile, as evidenced by Q4 2025's net income of just $10 million (EPS $0.011) versus Q1 2026's $6.28 billion (EPS $6.90). This volatility stems from medical cost trends and reserve adjustments. The debt-to-equity ratio of 0.83 is manageable, but interest expense of $955 million per quarter consumes a portion of operating income. Revenue growth has decelerated to 1.96% YoY, indicating a mature business with limited top-line expansion. The thin TTM net margin of 2.7% leaves little room for error, and any adverse claims experience could quickly erode profitability.
Market & Competitive Risks: UNH trades at a trailing P/E of 24.95x, a 13.4% premium to the industry average of 22.0x, which could compress if earnings disappoint. The stock's beta of 0.63 provides some insulation from market swings, but sector rotation out of healthcare could still pressure the stock. The ongoing DOJ investigation into Medicare billing practices is a significant overhang, and any negative news could trigger a sharp selloff. Additionally, regulatory changes to Medicare Advantage reimbursement rates pose a recurring risk, as seen in the Q4 2025 disruption.
Worst-Case Scenario: If the DOJ investigation results in substantial fines or operational restrictions, and Medicare reimbursement rates are cut, UNH could see earnings collapse. The 52-week low of $234.60 represents a potential 44.9% downside from the current price of $426.09. Analyst low target of $287.00 implies a 32.6% decline. In a severe scenario, the stock could revisit its 52-week low, resulting in a loss of approximately $191.49 per share (-44.9%).
FAQ
The primary risk is the ongoing DOJ investigation into Medicare billing practices, which could result in fines or operational restrictions. Second, UNH's earnings are highly sensitive to government Medicare reimbursement rates; any adverse policy changes could compress margins. Third, revenue growth is decelerating (1.96% YoY in Q1 2026), limiting top-line momentum. Fourth, the stock's thin net margin of 2.7% (TTM) leaves little room for error, and any spike in medical costs could quickly erode profitability. The DOJ investigation is the most severe risk, with potential to drive the stock down to the 52-week low of $234.60.
The 12-month outlook is balanced: a 50% probability of a base case where UNH trades near the average analyst target of $437.81, a 25% probability of a bull case reaching $492 (driven by favorable DOJ resolution), and a 25% probability of a bear case falling to $287 or lower (driven by adverse investigation outcomes). The base case is most likely, assuming the DOJ investigation drags on without resolution and revenue growth remains around 2-3%. The key assumption is that UNH's operational recovery continues, but regulatory overhangs prevent significant multiple expansion.
UnitedHealth's trailing P/E of 24.95x is above the industry average of 22.0x, indicating a slight premium justified by its market leadership and diversified business model. However, the P/B ratio of 3.19x is well below the 5-year average of 5.0x, suggesting the stock is cheap on a book value basis. The forward P/E of 19.38x implies the market expects earnings growth of about 22.3% over the next year. Overall, UNH appears fairly valued given its growth trajectory and risk profile, with no clear evidence of overvaluation or undervaluation.
UnitedHealth is a high-quality business with strong free cash flow ($19.67 billion TTM) and a reasonable trailing P/E of 24.95x, but the stock has already rallied 47.9% over the past year and trades near its 52-week high. The average analyst target of $437.81 implies only 2.7% upside, suggesting limited near-term gains. The biggest downside risk is the unresolved DOJ investigation, which could lead to fines or operational disruptions. For long-term investors with a 3-5 year horizon, UNH is a solid defensive holding, but for short-term traders, the risk-reward is less attractive given the limited upside and regulatory overhang.
UnitedHealth is best suited for long-term investment due to its defensive business model (beta 0.63), strong free cash flow, and consistent dividend growth (yield 2.64%). The stock's low volatility and essential healthcare services make it a core holding for long-term portfolios. Short-term trading is less attractive given the limited upside to the average analyst target (2.7%) and the unresolved DOJ investigation, which could cause sudden swings. A minimum holding period of 3-5 years is recommended to allow the company to compound earnings and resolve regulatory uncertainties.